Posted by Michael Wonder on 24 Aug 2017
Octapharma USA announces FDA approval of Nuwiq new product strengths, expanding haemophilia A patient treatment options
22 August 2017 - New higher vial strengths will provide added dosing flexibility & convenience.
Octapharma USA today announced the U.S. FDA has approved new product strengths for NUWIQ®, including 2500 International Units.
The agency approved new single dose Nuwiq vial strengths of 2,500, 3,000 and 4,000 International Units (IU), which will be available for ordering in the U.S. starting September 2017. These new vial strengths will be provided in addition to the already available strengths of 250, 500, 1,000 or 2,000 IU. Nuwiq is the only recombinant Factor VIII providing patients a wide array of vials with the lowest diluent volume of 2.5 mL.
